BRD2 and neoplasm: Since we used a personalized tumor-informed ctDNA test based on patient-specific tumor variants identified in pretreatment tumors (PT0), we assessed whether NAT-mediated selection pressures impacted the presence of these variants in NAT-resistant tumors over time.